Comparative Pharmacology
Head-to-head clinical analysis: GRALISE versus RELGAABI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GRALISE versus RELGAABI.
GRALISE vs RELGAABI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gabapentin is a structural analogue of GABA, but it does not bind to GABA-A or GABA-B receptors. It is thought to exert its antiepileptic and analgesic effects by binding to the alpha-2-delta subunit of voltage-gated calcium channels, inhibiting calcium influx and reducing neurotransmitter release.
Relgaabi (relugolix) is a gonadotropin-releasing hormone (GnRH) receptor antagonist. It competitively binds to GnRH receptors in the pituitary gland, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, thereby suppressing testosterone and estradiol levels.
Administer orally once daily with evening meal: start at 300 mg on day 1, 600 mg on day 2, then 900 mg on days 3-6, then 1200 mg on days 7-10, then 1500 mg on days 11-14, then 1800 mg daily thereafter. For postherpetic neuralgia, titrate up to 1800 mg orally once daily with evening meal.
13.2 mg/kg intravenously as a single dose, maximum 1000 mg.
None Documented
None Documented
Terminal half-life: 5-7 hours in patients with normal renal function; prolonged in renal impairment (up to 32 hours in ESRD).
Terminal elimination half-life: 14-18 hours in healthy adults; prolonged in renal impairment (up to 40 hours).
Renal elimination: >95% of absorbed dose excreted unchanged in urine.
Primarily renal excretion (80% unchanged) with 15% biliary/fecal elimination.
Category C
Category C
Gabapentinoid Anticonvulsant
Gabapentinoid Anticonvulsant